Autoantibodies to CD69 in patients with chronic hepatitis type C: A candidate marker for predicting the response to interferon therapy

Intervirology

Volumn 46, Issue 1, 2003, Pages 56-65

  Okamoto, Nahoko ^a   Yotsuyanagi, Hiroshi ^a   Ooka, Seido ^a   Matsui, Toshihiro ^a,b   Kurokawa, Manae Suzuki ^a,c   Suzuki, Michihiro ^a   Iino, Shiro ^a   Nishioka, Kusuki ^a   Kato, Tomohiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b SAGAMIHARA NATIONAL HOSPITAL   (Japan)

^c KITASATO INSTITUTE   (Japan)

Author keywords

Autoantibody; Autoimmunity; CD69; Chronic hepatitis C; Hepatitis C virus; Interferon

Indexed keywords

ALPHA INTERFERON; AUTOANTIBODY; CD69 ANTIGEN; RECOMBINANT ANTIGEN;

ADULT; AGED; ANTIBODY PRODUCTION; ARTICLE; AUTOIMMUNE HEPATITIS; CONTROLLED STUDY; DISEASE MARKER; EPITOPE MAPPING; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; VIRUS CARRIER;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOANTIBODIES; BIOLOGICAL MARKERS; EPITOPE MAPPING; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED;

HEPATITIS C VIRUS;

EID: 0037265648     PISSN: 03005526     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068126     Document Type: Article

References (37)

1. Orland JR, Wright TL, Cooper S: Acute hepatitis C. Hepatology 2001;33:321-327.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, Hu PY, Miller JK, Gerber MA, Sampliner RE, Meeks EL, Beach MJ: The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-1905.
3. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, Hollinger FB, Gitnick G, Knodell RG, Perrillo RP, Stevens CE, Hollingsworth CG: Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung and Blood Institute Study Group. N Engl J Med 1992;327:1906-1911.
4. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T: Natural history of chronic hepatitis C. Am J Gastroenterol 1993;88:240-243.
5. Tong MJ, el-Farra NS, Reikes AR, Co RL: Clinical outcomes after transfusion associated hepatitis C. N Engl J Med 1995;332:1463-1466.
6. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K: The long-term pathological evolution of chronic hepatitis C. Hepatology 1996;23:1334-1340.
7. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
8. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, Nevens F, Solinas A, Mura D, Brouwer JT, Thomas H, Njapoum C, Casarin C, Bonetti P, Fuschi P, Basho J, Tocco A, Bhala A, Galassini R, Noventa F, Schalm SW, Realdi G: Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-472.
9. Ikeda K, Saitoh S, Suzuki Y, Kobayashi M, Tsubota A, Koida I, Arase Y, Fukuda M, Chayama K, Murashima N, Kumada H: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2,215 patients. J Hepatol 1998;28:930-938.
10. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. N Engl J Med 1999;342:1228-1234.
11. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, Johnson LD: 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000;132:105-112.
12. Starzl TE, Zinkernagel RM: Antigen localization and migration in immunity and tolerance. N Engl J Med 1998;339:1905-1913.
13. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houston M, Ralston R, Walker BD: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992;149:3339-3344.
14. Liaw YF, Lee CS, Tsai SL, Liaw BW, Chen TC, Sheen IS, Chu CM: T-cell-mediated autologous hepatocytotoxicity in patients with chronic hepatitis C virus infection. Hepatology 1995;22:1368-1373.
15. Nelson DR, Marousis CG, Davis GL, Rice CM, Wong J, Houghton M, Lau JY: The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C. J Immunol 1997;158:1473-1481.
16. Cerny A, Chisari FV: Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology 1999;30:595-601.
17. Bertoletti A, Maini MK: Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Curr Opin Immunol 2000;12:403-408.
18. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, Muratori L, Lenzi M, Bianchi G, Zauli D, Bianchi FB: Serum autoantibodies in chronic hepatitis C: Comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26:561-566.
19. Cacoub P, Renou C, Rosenthal E, Cohen P, Loury I, Loustaud-Ratti V, Yamamoto AM, Camproux AC, Hausfater P, Musset L, Veyssier P, Raguin G, Piette JC: Extrahepatic manifestations associated with hepatitis C virus infection. A prospective multicenter study of 321 patients. The GERMIVIC. Medicine (Baltimore) 2000;79:47-56.
20. Quaranta JF, Tran A, Regnier D, Letestu R, Beusnel C, Fuzibet JG, Thiers V, Rampal P: High prevalence of antibodies to hepatitis C virus in patients with anti-thyroid autoantibodies. J Hepatol 1993;18:136-138.
21. Ganne-Carrie N, Medini A, Coderec E, Seror O, Christidis C, Grimbert S, Trinchet JC, Beaugrand M: Latent autoimmune thyroiditis in untreated patients with HCV chronic hepatitis: A case-control study. J Autoimmun 2000;14:189-193.
22. Winfield JB, Shaw M, Minota S: Modulation of IgM anti-lymphocyte antibody-reactive T cell surface antigens in systemic lupus erythematosus. J Immunol 1986;136:3246-3253.
23. Morimoto C, Abe T, Toguchi T, Kiyotaki M, Honma M: Studies of anti-lymphocyte antibody in patients with active SLE. II. Effect of anti-lymphocyte antibody on autoreactive cell clones. Scand J Immunol 1980;11:479-488.
24. Yu X, Matsui T, Otsuka M, Sekine T, Yamamoto K, Nishioka K, Kato T: Anti-CD69 autoantibodies cross react with low density lipoprotein receptor-related protein 2 in systemic autoimmune disease. J Immunol 2001;166:1360-1369.
25. Grabowska AM, Lechner F, Klenerman P, Tighe PJ, Ryder S, Ball JK, Thomson BJ, Irving WL, Robins RA: Direct ex vivo comparison of the breadth and specificity of the T cells in the liver and peripheral blood of patients with chronic HCV infection. Eur J Immunol 2001;31:2388-2394.
26. Ishihara S, Nieda M, Kitayama J, Osada T, Yabe T, Ishikawa Y, Nagawa H, Muto T, Juji T: CD8(+)NKR-P1A(+)T cells preferentially accumulate in human liver. Eur J Immunol 1999;29:2406-2413.
27. He XS, Rehermann B, Lopez-Labrador FX, Boisvert J, Cheung R, Mumm J, Wedemeyer H, Berenguer M, Wright TL, Davis MM, Greenberg HB: Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers. Proc Natl Acad Sci USA 1999;96:5692-5697.
28. Tran A, Yang G, Doglio A, Ticchioni M, Laffont C, Durant J, Bernard JL, Gugenheim J, Saint-Paul MC, Bernard A, Rampal P, Benzaken S: Phenotyping of intrahepatic and peripheral blood lymphocytes in patients with chronic hepatitis C. Dig Dis Sci 1997;42:2495-2500.
29. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
30. Bedossa P, Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293.
31. Yamamoto K, Miura H, Moroi Y, Yoshinoya S, Goto M, Nishioka K, Miyamoto T: Isolation and characterization of a complementary DNA expressing human U1 small nuclear ribonucleoprotein C polypeptide. J Immunol 1988;140:311-317.
32. Lunel F, Cacoub P: Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection. J Hepatol 1999;31:210-216.
33. Martinot-Peignox M, Boyer N, Pouteau M, Castelnau C, Giuily N, Duchatelle V, Auperin A, Degott C, Benhamou JP, Erlinger S, Marcellin P: Predictors of sustained response to alpha interferon therapy in chronic hepatitis C. J Hepatol 1998;29:214-223.
34. Herberman RB: Effect of α-interferons on immune function. Semin Oncol 1997;24(3 suppl 9):S9-78-S9-80.
35. Morris A, Zvetkova I: Cytokine research: The interferon paradigm. J Clin Pathol 1997;50:635-639.
36. Davis JL, Lau JYN: Predictive factors for a beneficial response. NIH Consensus Development Conference: Management of Hepatitis C. Hepatology 1997;26:113-117.
37. Iino S, Hino K, Yasuda K: Current state of interferon therapy for chronic hepatitis C. Intervirology 1994;37:87-100.